Skip to content
Business
Prognosis

Antibody Cocktails to Treat Covid Take Off as Delta Surges

  • 70% of American population eligible; quick shots add momentum
  • With timing key, new approval also allows ‘morning after’ use
Medical supplies used to administer the monoclonal antibody treatment REGEN-COV.
Medical supplies used to administer the monoclonal antibody treatment REGEN-COV.Photographer: Kayana Szymczak/Bloomberg

Outside, in letters a foot tall, the wall of the trailer reads: “GET TESTED. GET TREATED. CRUSH COVID.” Inside, leathery recliners cradle patients as a freshly mixed concoction drips into their veins: a combination of two monoclonal antibodies once used so rarely that when President Donald Trump got it last October, it ignited accusations of special treatment.

Now, amid the delta variant surge, the cocktail is rapidly becoming a more common, even routine medical response to a positive coronavirus test in a high-risk patient. Federal and state officials are promoting it, particularly in hard-hit areas, and demand has exploded from a trickle to more than 120,000 doses a week by the latest count from its maker, Regeneron Pharmaceuticals Inc.